Skip to content
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
Home/Events/Clinical Trial Supply China 2026
EventsConferences

Clinical Trial Supply China 2026

By Henry Tseng
August 26, 2026 1 Min Read
0

Clinical Trial Supply China is returning for a second year! This is your gateway to understanding and excelling in the rapidly evolving landscape of clinical trial logistics in China.

Why attend?

Navigate Local Challenges: Gain critical insights into the unique complexities of clinical trial supply chains in China, including import/export regulations, regional distribution, and local manufacturing.

Regulatory Expertise: Stay updated on China’s regulatory environment, ensuring compliance while minimizing delays and risks in your clinical trial supply processes.

Build Strategic Partnerships: Connect with key stakeholders, including suppliers, logistics providers, and biopharmaceutical companies, to foster collaborations that drive efficiency and innovation.

Discover Innovative Solutions: Explore cutting-edge tools, technologies, and strategies to optimize supply chain management, ensure product integrity, and reduce operational costs.

Stay Ahead of Trends: Learn about emerging trends and future directions in clinical trial supply tailored specifically to the Chinese market.

Whether you’re launching trials in China or looking to refine your supply chain operations, this conference provides the knowledge and connections you need to thrive in one of the most dynamic markets for clinical trials.

Dates: Sept. 8–9, 2026

Location: Renaissance Suzhou Hotel, Suzhou, China

REGISTER
Other Articles
Previous

CBI 2026 – Antibody Drug Development Conference

Next

CPHI & PMEC Shenzhen 2026

No Comment! Be the first one.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

2026 H2 AbbVie China Partnering Day
2026 Global XDC Innovation Conference

Welcome to BioPharmChina, a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

Get the latest news in China's BioPharma industry delivered straight to your inbox.

Latest Articles

  • Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
  • Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
  • 1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
  • Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
  • Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3

Info

    About

    Privacy Policy

    Terms of Use

    Newsletter

    Contact

    Contact

    Email
    contact@biopharmchina.com

    Location
    San Francisco, CA, USA

    • X
    • Facebook
    Copyright 2026 — BioPharmChina. All rights reserved.